Short answer
ANI PHARMACEUTICALS INC (ANIP) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $228M (up 53.6% year over year) with net income of $27M.
Q3 2025 key financials · XBRL
- Revenue
- $228M
- +53.6% YoY · +7.8% QoQ
- Net income
- $27M
- +210.1% YoY · +211.3% QoQ
- Operating margin
- 15.9%
- EPS (diluted)
- $1.10
- +192.4% YoY · +205.6% QoQ
Source: XBRL data from the ANI PHARMACEUTICALS INC (ANIP) Q3 2025 10-Q on SEC EDGAR. USD.
ANI PHARMACEUTICALS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- NEW risk: acquisition and integration of Alimera Sciences in Sept 2024, expanding product portfolio with ILUVIEN and YUTIQ, adding commercial/regulatory complexity
- Material update: expanded FDA label for ILUVIEN in Mar 2025 to include chronic NIU-PS, increasing market opportunity and promotional efforts
- Regulatory risk: approval and marketing compliance for new drug presentation Cortrophin Gel prefilled syringes approved Feb 2025, requiring updated manufacturing/supply chain controls
- Market risk: increased pricing and volume competition in generics expected in Q4 2025, potentially reducing generic product revenues following 17 new product launches in 2024
- Financial risk: exercised $17.3M buy-out of royalty obligation to SWK in Mar 2025, eliminating future royalty payments but utilizing cash resources
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANI PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.